CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate

Lyons J, Hughes R, McCarthy K, Everage N, Kapadia S, Miller C, Singhal P, Smirnakis K. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. Mult Scler J Exp Transl Clin. 2022 Nov 10;8(4). doi: 10.1177/20552173221132469.

The author would like to alert readers to the following correction:

In the above referenced article, on page 5, first paragraph of column 2, we request that the sentence,

‘The patient had received DMF 240 mg three times daily for 2 years in the DEFINE clinical trial and was exposed to DMF 240 mg twice daily for 2.5 years in the ENDORSE open-label extension of the DEFINE clinical trial, for a total of 4.5 years of DMF treatment.’

be changed to

‘The patient had received DMF 240 mg three times daily for the first 2 years of ENDORSE and then was switched to DMF 240 mg twice daily for 2.5 years, for a total of 4.5 years of DMF treatment.’